Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 548 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Can Getting a “Base Tan” Protect You From Sunburn and Skin... March 30, 2023 FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular... March 22, 2024 Proof of Concept for the Safety and Immunogenicity of Lymph Node... January 18, 2024 Cancer, COVID-19, and Competing Threats to Indigenous Health July 20, 2020 Load more HOT NEWS Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020 Avapritinib Approved to Treat GIST with a Rare Gene Alteration Will Ponsegromab Be a Game Changer for Cancer Cachexia? New on NCI’s Websites for September 2020
